Blue September is the Prostate Cancer Foundation's National Awareness Campaign. Every year around 3,000 men are diagnosed with prostate cancer in New Zealand and more than 600 will die. That’s about the same number as women who die from breast cancer.
The good news is that early detection can significantly reduce the risk of death from prostate cancer. Mostly, men don’t know how dangerous this disease is – patients don’t talk to their doctor about it, doctors don’t talk to patients about it. Sometimes patients simply don’t have any symptoms and don’t feel unwell.
If you haven’t been directly affected by prostate cancer, you’re bound to know someone who has. We are helping to raise awareness on this illness. Every little bit helps to provide support, campaign for greater awareness, and advocate for better diagnosis and treatment outcomes.
To find out more about Blue September, or to show your support, click here.
Thanks to medical advancements, there are more treatment options for prostate cancer patients these days. Unfortunately, not all are covered by the public health system in New Zealand.
Matt shares his story here:
Prostate Brachytherapy is a minimally invasive treatment for low and intermediate risk prostate cancer. Derived from the Greek term “brakhus” which means short, the procedure is a form of radiation therapy which delivers cancer killing radiation in the form of implanted radioactive “seeds” of iodine. Recovery time is short and it is a day-stay procedure minimising the impact on your daily life.
This treatment is covered under some private health policies, but it is not available via the public health system. This is one of the reasons private health insurance can make a difference. Insurance is not a cost, it's a safeguard. It's us taking charge of our own finances and the financial safety of our loved ones.
If you have been thinking about whether or not you should get health insurance, contact us and we can walk you through the details, so that you can make better calls for you and your loved ones.